Posted by Michael Wonder on 06 Jan 2017
FDA approves Genentech’s Lucentis (ranibizumab) for myopic choroidal neovascularisation
5 January 2017 - Granted priority review by the FDA.
Genentech announced today that the U.S. FDA has approved Lucentis (ranibizumab) 0.5 mg for the treatment of patients with myopic choroidal neovascularisation, a complication of severe near-sightedness that can lead to blindness.
Lucentis is the first FDA-approved anti-vascular endothelial growth factor therapy to treat mCNV in the U.S. This is the fifth FDA-approved indication for Lucentis since the medicine was launched in 2006.
